| scholarly article | Q13442814 |
| P2093 | author name string | Marc C Smaldone | |
| Jeffrey J Tomaszewski | |||
| P2860 | cites work | Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer | Q24247924 |
| Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion | Q28350937 | ||
| Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study | Q30888685 | ||
| Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience | Q32027039 | ||
| Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma | Q33216260 | ||
| Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. | Q33343442 | ||
| Mitomycin C: mechanism of action, usefulness and limitations | Q33394077 | ||
| Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer | Q33500776 | ||
| BCG intravesical instillations: recommendations for side-effects management | Q33781023 | ||
| Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy | Q33901316 | ||
| Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group | Q33928041 | ||
| Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer | Q34062336 | ||
| Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma | Q34272640 | ||
| Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study | Q34340826 | ||
| Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract | Q34425387 | ||
| Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer | Q34563433 | ||
| Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results | Q34667307 | ||
| Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer | Q34779084 | ||
| A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder | Q34946650 | ||
| Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. | Q35685707 | ||
| Current and new strategies in immunotherapy for superficial bladder cancer | Q35879902 | ||
| Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells | Q36617339 | ||
| Intravesical treatments of bladder cancer: review. | Q36738254 | ||
| A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study | Q36784305 | ||
| The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society | Q36823493 | ||
| Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update | Q36997480 | ||
| EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder | Q37158767 | ||
| Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer | Q37222380 | ||
| Gene therapy in bladder cancer | Q37231629 | ||
| Risk-adapted use of intravesical immunotherapy. | Q37335474 | ||
| Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. | Q37457553 | ||
| Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. | Q37487550 | ||
| Combination of BCG and interferon intravesical immunotherapy: an update. | Q37500031 | ||
| Definition and management of patients with bladder cancer who fail BCG therapy | Q37508032 | ||
| Investigational therapies for non-muscle invasive bladder cancer | Q37676223 | ||
| Clinical model of lifetime cost of treating bladder cancer and associated complications | Q40287842 | ||
| CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer | Q40333228 | ||
| Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study | Q40496147 | ||
| Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder | Q40506004 | ||
| Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial | Q40550087 | ||
| Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells | Q40561027 | ||
| Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine | Q40591664 | ||
| Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer | Q40591676 | ||
| Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer geni | Q40599599 | ||
| Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. | Q40629967 | ||
| Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study | Q40750923 | ||
| A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary ca | Q40887451 | ||
| Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer | Q41360899 | ||
| Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial | Q43254447 | ||
| Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance | Q43258593 | ||
| Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study | Q43263933 | ||
| Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model | Q43544155 | ||
| A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer--intravesical thio-TEPA versus oral UFT | Q67552734 | ||
| Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures | Q68028164 | ||
| A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer | Q68936844 | ||
| Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients | Q70256311 | ||
| Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial | Q70428731 | ||
| Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa | Q70445702 | ||
| Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer | Q71083098 | ||
| The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up | Q71083101 | ||
| The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder | Q71538830 | ||
| A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment | Q71764892 | ||
| Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instill | Q72539404 | ||
| Taxol and taxotere in bladder cancer: in vitro activity and urine stability | Q72672232 | ||
| Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder | Q73082789 | ||
| Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations | Q73287980 | ||
| Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study | Q73354099 | ||
| Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group | Q73477207 | ||
| Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers | Q73515435 | ||
| Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder | Q73617894 | ||
| Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial | Q73773999 | ||
| Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study | Q73798367 | ||
| Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study | Q73828534 | ||
| Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer | Q73931771 | ||
| Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer | Q74107594 | ||
| Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials | Q74170098 | ||
| What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer? | Q74218227 | ||
| Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial | Q74246062 | ||
| Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients | Q74328584 | ||
| Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study | Q74337157 | ||
| Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed | Q74486091 | ||
| Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy? | Q74581854 | ||
| Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder | Q77086502 | ||
| A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa | Q77357476 | ||
| Intravesical therapy for superficial bladder cancer: slow but steady progress | Q79214354 | ||
| Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy | Q79816348 | ||
| Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer | Q79832999 | ||
| Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma | Q80030411 | ||
| What is the optimal BCG dose in non-muscle-invasive bladder cancer? | Q80389463 | ||
| The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy | Q80438935 | ||
| Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy | Q80792631 | ||
| Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial | Q81170471 | ||
| Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial | Q82150860 | ||
| Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer | Q82515315 | ||
| Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed | Q83198627 | ||
| Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials | Q83961773 | ||
| Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent | Q94701661 | ||
| Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. | Q43573165 | ||
| Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer | Q43720370 | ||
| Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer | Q44075876 | ||
| Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study--FinnBladder III long-term result | Q44108645 | ||
| Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity | Q44246166 | ||
| Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. | Q44285258 | ||
| Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall | Q44403383 | ||
| Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase | Q44508783 | ||
| A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder | Q44686660 | ||
| Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes | Q44686696 | ||
| Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer | Q44767727 | ||
| Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study | Q44870028 | ||
| Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies | Q44872291 | ||
| A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials | Q44883456 | ||
| Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). | Q45014818 | ||
| Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival | Q45079238 | ||
| Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model | Q45526738 | ||
| Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy | Q45862912 | ||
| Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model | Q45885364 | ||
| Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. | Q45967681 | ||
| The invasive T1 bladder tumor: contemporary issues and rationale for radical cystectomy. | Q46005364 | ||
| Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. | Q46114623 | ||
| The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience | Q46123240 | ||
| Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens | Q46184154 | ||
| A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. | Q46489296 | ||
| Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials | Q46538062 | ||
| Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. | Q46634696 | ||
| Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes | Q46990349 | ||
| Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study | Q47642049 | ||
| The effect of fasting or desmopressin before treatment on the concentration of mitomycin C during intravesical administration. | Q51552804 | ||
| Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. | Q51953901 | ||
| Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. | Q52544224 | ||
| Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. | Q53617199 | ||
| Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. | Q53715480 | ||
| Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. | Q54145282 | ||
| Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response | Q56786810 | ||
| Preliminary European Results of Local Microwave Hyperthermia and Chemotherapy Treatment in Intermediate or High Risk Superficial Transitional Cell Carcinoma of the Bladder | Q57307272 | ||
| Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group | Q57905078 | ||
| Intravesical Thiotepa versus Mitomycin C in Patients with TA, T1 and TIS Transitional Cell Carcinoma of the Bladder: A Phase III Prospective Randomized Study | Q60355495 | ||
| The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict its Efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial | Q64111965 | ||
| Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials | Q64112022 | ||
| Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation | Q64379153 | ||
| [Preliminary results of a multicenter study with mitomycin C in superficial bladder tumors (Ta, T1)] | Q67233458 | ||
| Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer | Q67271686 | ||
| Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma | Q67520941 | ||
| P921 | main subject | bladder cancer | Q504775 |
| P304 | page(s) | 67-84 | |
| P577 | publication date | 2010-05-19 | |
| P1433 | published in | Open Access Journal of Urology | Q15816467 |
| P1476 | title | Emerging intravesical therapies for management of nonmuscle invasive bladder cancer | |
| P478 | volume | 2 |
| Q27023406 | Targeting Hsp90 in urothelial carcinoma | cites work | P2860 |
Search more.